Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day

Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study

by Zacks Equity Research

Lilly (LLY) announces data from a phase II study on its Alzheimer's disease candidate, donanemab, which shows slowing of cognitive decline.

The Zacks Analyst Blog Highlights: Roche, BlackRock, Square, Infosys and Moody's

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Roche, BlackRock, Square, Infosys and Moody's

Sheraz Mian headshot

Top Research Reports for Roche, BlackRock & Square

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Roche (RHHBY), BlackRock (BLK), and Square (SQ).

Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates

by Zacks Equity Research

Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.

BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy

by Zacks Equity Research

BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.

Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate

by Zacks Equity Research

Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates

by Kinjel Shah

AbbVie's (ABBV) Skyrizi succeeds in psoriatic arthritis and Crohn's disease studies. AstraZeneca (AZN), Pfizer (PFE) and Roche (RHHBY) give FDA updates.

Infinity (INFI) Provides Data on Eganelisib in Urothelial Cancer

by Zacks Equity Research

Infinity (INFI) provides an update on Eganelisib in patients with metastatic urothelial cancer.

Kinjel Shah headshot

3 Biotech Technological Developments to Watch Out For in 2021

by Kinjel Shah

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

Roche's (RHHBY) Immunotherapy Gets Breakthrough Therapy Status

by Zacks Equity Research

Roche's (RHHBY) tiragolumab in combination with Tecentriq wins Breakthrough Therapy designation for the first-line treatment of patients with metastatic non-small cell lung cancer.

Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance

by Zacks Equity Research

Pfizer's (PFE) BLA for growth hormone deficiency (GHD) gets accepted by the FDA for standard review. FDA's decision expected in October 2021.

Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal

by Zacks Equity Research

Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.

AstraZeneca's (AZN) Lynparza Approved in Japan for 3 Cancers

by Zacks Equity Research

AstraZeneca (AZN) and partner Merck's Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.

Pfizer (PFE) Lorbrena First-Line sNDA Gets FDA Priority Review

by Zacks Equity Research

Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets priority review from the FDA.

AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why

by Zacks Equity Research

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.

Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer

by Zacks Equity Research

Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.

Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study

by Zacks Equity Research

Exelixis' (EXEL) cabozantinib meets the co-primary endpoint in the late-stage study for the treatment of differentiated thyroid cancer following anti-VEGFR therapy.

Roche's (RHHBY) DME Drug Meets Primary Endpoint in Studies

by Zacks Equity Research

Roche's (RHHBY) investigational bispecific antibody, faricimab, meets the primary endpoints in two late-stage studies for diabetic acular edema.

Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why

by Zacks Equity Research

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.

    Roche (RHHBY) Gets FDA Nod for Shorter Infusion Time of Ocrevus

    by Zacks Equity Research

    The FDA approves Roche's (RHHBY) Ocrevus for two-hour infusion time, dosed twice-yearly to patients with relapsing or primary progressive MS.

    Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug

    by Zacks Equity Research

    Seagen (SGEN) gets a positive opinion from the CHMP, recommending the approval of Tukysa for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer.

    The Zacks Analyst Blog Highlights: Roche, Wells Fargo, General Electric, Microsoft and Intuit

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Roche, Wells Fargo, General Electric, Microsoft and Intuit

    Kinjel Shah headshot

    Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates

    by Kinjel Shah

    An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.

    Sheraz Mian headshot

    Top Stock Reports for Roche, Wells Fargo & General Electric

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Wells Fargo & Company (WFC) and General Electric Company (GE).